You are not logged in.
Please login to continue selecting trials.
Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaBehaviors and Mental DisordersEnrollment363% Female53%% White92%
Product ClassAnticonvulsantsSponsor Protocol NumberTOPMAT-PDMD-005 (CR002248)Data PartnerJohnson & JohnsonCondition StudiedBipolar DisorderMean/Median Age (Years)43
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- Heterogeneous treatment effects estimation with multi-source data: evidence from bipolar disorder and schizophrenia trials
- Psychiatric Symptoms as Adverse Events of Topiramate Therapy: Systematic Review and Meta-Analysis
- Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- Generalizing treatment effects for bipolar disorder and schizophrenia to the US population: Generalizability of network meta-analysis